Keeping Track: US FDA Clears Another CAR-T And Another Novel ADHD Drug; Submissions Blossom
Executive Summary
The latest news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.